The David Geffen School of Medicine (DGSoM)/Broad Stem Cell Research Center (BSCRC) provides Research Awards (RA) supports applications from UCLA faculty proposing innovative science that addresses COVID 19. The RA is not intended to replace currently funded efforts. The program provides six months of support. The DGSoM/BSCRC does not guarantee funding of any applications during a particular award cycle.

**ELIGIBILITY:**
- Only UCLA faculty (tenure track/“in-residence”) may apply for a COVID 19 RA
- An eligible PI may only submit one proposal on which s/he is named PI
- Collaborative proposals are strongly encouraged, however, a single lead PI must be named

**PROJECT TIMELINE & DELIVERABLES:**
- Awardee must be ready to initiate the research immediately and no later than two weeks following the issuance of the award letter.
- Applicants must propose an achievable clear, significant, and meaningful deliverable within three months of project initiation. Failure to achieve project milestones may result in rescinding of the award.

**AWARD DURATION:**
- A COVID 19 RA is a six month award.

**AWARDS TERMS:**
- Up to $250,000 to support direct research costs
- Funds are released in three month intervals based on mid-award progress report
- Eligible Costs:
  - Personnel costs (Research staff salaries and benefits only). PI/co-I salary or benefits are NOT allowable)
  - Supplies
  - Equipment will only be funded in exceptional cases with specific justification.
- Sharing of Biological Samples: Since the COVID 19 RA is intended to support research to address the pandemic crisis, in order to maximize the utility of the research, awardees are required to make collected biological material and related coded donor data available to the UCLA research community for further research.

**APPLICATION PROCESS:** The BSCRC COVID 19 RA includes a Letter of Intent (LOI). Investigators will be selected from eligible LOI applications. All Application materials must be in 11-point Arial type with one-inch margins and submitted electronically via submission form.

**The LOI must include:**
1. One to three page concise description of the research proposal, goals, and milestones. (Clinical Trials: Please include the trial protocol)
2. One page estimated total budget and general breakdown of projected expenses
3. Current biosketch in NIH format for PI and named Co-Investigators (5 page maximum.
4. Compliance Approvals for PI and each named Co-Investigator:
David Geffen School of Medicine/Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
COVID 19 Research Awards
Guidelines for Submission of an Application

- Animal Research Committee (ARC)
- Institutional Review Board (IRB)
- Human Pluripotent Stem Cell Research Oversight (hPSCRO) Committee
- Institutional Biosafety Committee (IBC)
- Other applicable compliance committees

5. PIs must submit applications directly to the BSCRC. (PLEASE NOTE: Submitting an application to the UCLA Office of Contracts & Grant Administration is NOT required and may result in missing deadlines.)

REVIEW PROCESS: Submitted documents are assessed by the DGSoM Oversight COVID 19 Research Committee and applicable Task Forces. The review process is confidential and applicants will not receive comments or scores.

PROGRESS REPORTS:
1. Since the COVID 19 RA is intended to address the current crisis, the second allocation of funds is released at three months based on the success of the project documented in your progress report. Investigators must submit:
   a. A three month scientific progress report (no more than one page) describing the demonstrable progress toward meeting the milestones and the ultimate goal of the deliverable.
   b. Financial report, and
   c. Reprints or submitted manuscripts resulting from the research.

2. Six Month Final Report: At the end of the funding period (six months), you are required to submit a final report consisting of:
   a. Scientific report – status of research and progress to date and achievement of milestones
   b. Financial report – inclusive of account balances for any transfers made from the Lead PI to collaborators.
   c. List of external funding applied to/received as a result of the Award
   d. List of publications made possible by the Award

COMPLIANCE COMMITTEES: Documentation of relevant compliance committee approval is required prior to the release of funds.

ACKNOWLEDGEMENTS: All publications and presentations resulting from research projects supported by the RA should acknowledge the "UCLA David Geffen School of Medicine - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program".

Applicants must complete and upload LOI in the submission form.